Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELDAY: Velcade in Advanced or Metastatic Solid Tumors
NCT02220049Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Dec 2010
- Primary completion
- Nov 2013
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bortezomib in solid tumor, sponsored by Gustave Roussy. Primary endpoint: Maximum Tolerated Dose up to 19 months. Started Dec 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02220049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220049.